Evidence map›Paper›PMID 42559341›Full record

ArticleTheranostics2026

Reshaping immune cell distribution with mRNA noncationic lipid nanoparticles for overcoming neoadjuvant chemo-immunotherapy resistance.

Yiwen Liu, Rui Chang, Kenan Chen, Lin Li, Xiaogang An, Shegan Gao, Dingjun Zha, Hongzhang Deng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yiwen LiuDepartment of Otolaryngology-Head and Neck Surgery, Xijing Hospital, Air Force Medical University, Xi'an, Shaanxi 710032, China.
Rui ChangAnyang Tumor Hospital, Anyang, Henan, China.
Kenan ChenAnyang Tumor Hospital, Anyang, Henan, China.
Lin LiEngineering Research Center of Molecular & Neuroimaging Ministry of Education, School of Life Science and Technology, Xidian University, Xi'an, Shaanxi, 710126, China.
Xiaogang AnDepartment of Otolaryngology-Head and Neck Surgery, Xijing Hospital, Air Force Medical University, Xi'an, Shaanxi 710032, China.
Shegan GaoCollege of Clinical Medicine, The First Affiliated Hospital, Henan University of Science and Technology, Luoyang 471003, Henan, China.
Dingjun ZhaDepartment of Otolaryngology-Head and Neck Surgery, Xijing Hospital, Air Force Medical University, Xi'an, Shaanxi 710032, China.
Hongzhang DengDepartment of Otolaryngology-Head and Neck Surgery, Xijing Hospital, Air Force Medical University, Xi'an, Shaanxi 710032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: Fusobacterium nucleatum (Fn) is associated with resistance to neoadjuvant chemo-immunotherapy in esophageal squamous cell carcinoma (ESCC), but the underlying mechanism is unclear. We identified Fn-induced SPP1⁺ macrophages as key drivers of a cancer-associated fibroblast (CAF)-mediated spatial immune barrier that restricts CD8⁺ T-cell infiltration. Methods: Mannose-modified non-cationic thiourea lipid nanoparticles (NC-TNP Results: NC-TNP Conclusions: Fn-induced SPP1⁺ macrophages drive immune exclusion and chemo-immunotherapy resistance in ESCC. Macrophage-targeted SPP1 editing with NC-TNP

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaNanoparticlesRNA, MessengerAnimalsCD8-Positive T-LymphocytesCell Line, TumorDrug Resistance, NeoplasmFusobacterium nucleatumHumansImmunotherapyLipidsLiposomesMacrophagesMiceLipid NanoparticlesLipidsLiposomesRNA, Messengeresophageal squamous cell carcinomaimmune cell distributionmacrophagemRNA deliveryneoadjuvant chemo-immunotherapy resistance

Identifiers

PMID42559341
PMCPMC13440642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.